Literature DB >> 11120972

Pharmacological basis for concentration-controlled therapy with zidovudine, lamivudine, and indinavir.

T N Kakuda1, L M Page, P L Anderson, K Henry, T W Schacker, F S Rhame, E P Acosta, R C Brundage, C V Fletcher.   

Abstract

Conventional antiretroviral therapy involves administration of standard fixed doses to adults and adolescents. This approach ignores interindividual variability in pharmacokinetics and results in substantial differences in systemic concentrations among patients. Thus, variability in systemic concentrations contributes to variability in response to therapy. This study was designed to evaluate the feasibility and safety of a regimen of zidovudine, lamivudine, and indinavir designed to achieve select target concentrations versus standard dose therapy. Twenty-four antiretroviral-naïve subjects completed the 24-week study; 13 received standard therapy, and 11 received concentration-controlled therapy. There were no differences in baseline characteristics. Oral clearance for all three drugs was not different between weeks 2 and 28; average ratios of week 2 oral clearance to week 28 oral clearance were 0.95, 1.09, and 1.06 for zidovudine, lamivudine, and indinavir, respectively, with 95% confidence intervals including 1. The selected target concentrations were average steady-state concentrations of 0.19 mg/liter for zidovudine and 0.44 mg/liter for lamivudine and a trough concentration of 0.15 mg/liter for indinavir; mean concentrations achieved at week 28 in the concentration-controlled arm were 0.20, 0.54, and 0.19 mg/liter, respectively. Concentration-controlled therapy significantly reduced interpatient variability in zidovudine concentrations and significantly increased indinavir concentrations. There was no difference in adverse drug effects or adherence. This investigation has provided a pharmacologic basis for concentration-controlled therapy by demonstrating that it is feasible and has a safety profile no different from that of standard therapy. Additional studies to evaluate the virologic effect of the concentration-controlled approach to antiretroviral therapy are warranted.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11120972      PMCID: PMC90267          DOI: 10.1128/AAC.45.1.236-242.2001

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  33 in total

1.  Decreased and variable systemic availability of zidovudine in patients with AIDS if administered with a meal.

Authors:  E Lotterer; M Ruhnke; M Trautmann; R Beyer; F E Bauer
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

2.  Relationships between exposure to saquinavir monotherapy and antiviral response in HIV-positive patients.

Authors:  R Gieschke; B Fotteler; N Buss; J L Steimer
Journal:  Clin Pharmacokinet       Date:  1999-07       Impact factor: 6.447

Review 3.  Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA Panel.

Authors:  C C Carpenter; D A Cooper; M A Fischl; J M Gatell; B G Gazzard; S M Hammer; M S Hirsch; D M Jacobsen; D A Katzenstein; J S Montaner; D D Richman; M S Saag; M Schechter; R T Schooley; M A Thompson; S Vella; P G Yeni; P A Volberding
Journal:  JAMA       Date:  2000-01-19       Impact factor: 56.272

4.  Adherence to protease inhibitor therapy and outcomes in patients with HIV infection.

Authors:  D L Paterson; S Swindells; J Mohr; M Brester; E N Vergis; C Squier; M M Wagener; N Singh
Journal:  Ann Intern Med       Date:  2000-07-04       Impact factor: 25.391

5.  Simulation of linear compartment models with application to nuclear medicine kinetic modeling.

Authors:  D Z D'Argenio; A Schumitzky; W Wolf
Journal:  Comput Methods Programs Biomed       Date:  1988 Jul-Aug       Impact factor: 5.428

6.  Relation between plasma concentrations of didanosine and markers of antiviral efficacy in adults with AIDS or AIDS-related complex.

Authors:  M Beltangady; C A Knupp; N Gustafson; R H Barbhaiya; R Dolin; M Seidlin; T P Cooley; M Rozencweig
Journal:  Clin Infect Dis       Date:  1993-02       Impact factor: 9.079

7.  Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations.

Authors:  K Yamaoka; T Nakagawa; T Uno
Journal:  J Pharmacokinet Biopharm       Date:  1978-04

8.  Pharmacologic characteristics of indinavir, didanosine, and stavudine in human immunodeficiency virus-infected children receiving combination therapy.

Authors:  C V Fletcher; R C Brundage; R P Remmel; L M Page; D Weller; N R Calles; C Simon; M W Kline
Journal:  Antimicrob Agents Chemother       Date:  2000-04       Impact factor: 5.191

9.  Pharmacokinetics of oral zidovudine (azidothymidine) in patients with AIDS when administered with and without a high-fat meal.

Authors:  J D Unadkat; A C Collier; S S Crosby; D Cummings; K E Opheim; L Corey
Journal:  AIDS       Date:  1990-03       Impact factor: 4.177

10.  Cellular pharmacology of 2',3'-dideoxy-2',3'-didehydrothymidine, a nucleoside analog active against human immunodeficiency virus.

Authors:  H T Ho; M J Hitchcock
Journal:  Antimicrob Agents Chemother       Date:  1989-06       Impact factor: 5.938

View more
  25 in total

1.  Clinical Pharmacologic Considerations for HIV-1 Protease Inhibitors.

Authors:  Peter L. Anderson; Courtney V. Fletcher
Journal:  Curr Infect Dis Rep       Date:  2001-08       Impact factor: 3.725

2.  Stable concentrations of zidovudine, stavudine, lamivudine, abacavir, and nevirapine in serum and cerebrospinal fluid during 2 years of therapy.

Authors:  Rieneke M E van Praag; Elisabeth C M van Weert; Rolf P G van Heeswijk; Xiao-Jian Zhou; Jean-Pierre Sommadossi; Suzanne Jurriaans; Joep M A Lange; Richard M W Hoetelmans; Jan M Prins
Journal:  Antimicrob Agents Chemother       Date:  2002-03       Impact factor: 5.191

3.  Quality assurance program for clinical measurement of antiretrovirals: AIDS clinical trials group proficiency testing program for pediatric and adult pharmacology laboratories.

Authors:  Diane T Holland; Robin DiFrancesco; Judith Stone; Fayez Hamzeh; James D Connor; Gene D Morse
Journal:  Antimicrob Agents Chemother       Date:  2004-03       Impact factor: 5.191

4.  Pharmacokinetic Modeling of Lamivudine and Zidovudine Triphosphates Predicts Differential Pharmacokinetics in Seminal Mononuclear Cells and Peripheral Blood Mononuclear Cells.

Authors:  Julie B Dumond; Kuo H Yang; Racheal Kendrick; Y Sunila Reddy; Angela D M Kashuba; Luigi Troiani; Arlene S Bridges; Susan A Fiscus; Alan Forrest; Myron S Cohen
Journal:  Antimicrob Agents Chemother       Date:  2015-08-03       Impact factor: 5.191

5.  High variability of indinavir and nelfinavir pharmacokinetics in HIV-infected patients with a sustained virological response on highly active antiretroviral therapy.

Authors:  Cécile Goujard; Mayeule Legrand; Xavière Panhard; Bertrand Diquet; Xavier Duval; Gilles Peytavin; Isabelle Vincent; Christine Katlama; Catherine Leport; Bénédicte Bonnet; Dominique Salmon-Céron; France Mentré; Anne-Marie Taburet
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

6.  Impact of censoring data below an arbitrary quantification limit on structural model misspecification.

Authors:  Wonkyung Byon; Courtney V Fletcher; Richard C Brundage
Journal:  J Pharmacokinet Pharmacodyn       Date:  2007-10-26       Impact factor: 2.745

7.  Intracellular accumulation of human immunodeficiency virus protease inhibitors.

Authors:  Saye H Khoo; Patrick G Hoggard; Ian Williams; E Rhiannon Meaden; Philippa Newton; Edmund G Wilkins; Alan Smith; John F Tjia; Judy Lloyd; Kevin Jones; Nick Beeching; Peter Carey; Barry Peters; David J Back
Journal:  Antimicrob Agents Chemother       Date:  2002-10       Impact factor: 5.191

8.  Cytokine and sex hormone effects on zidovudine- and lamivudine-triphosphate concentrations in vitro.

Authors:  Peter L Anderson; Tracy King; Jia-Hua Zheng; Samantha MaWhinney
Journal:  J Antimicrob Chemother       Date:  2008-06-20       Impact factor: 5.790

9.  Population pharmacokinetics of indinavir in patients infected with human immunodeficiency virus.

Authors:  Chantal Csajka; Catia Marzolini; Karin Fattinger; Laurent A Décosterd; Amalio Telenti; Jérôme Biollaz; Thierry Buclin
Journal:  Antimicrob Agents Chemother       Date:  2004-09       Impact factor: 5.191

10.  Benefit of therapeutic drug monitoring of protease inhibitors in HIV-infected patients depends on PI used in HAART regimen--ANRS 111 trial.

Authors:  Xavier Duval; France Mentré; Elisabeth Rey; Solange Auleley; Gilles Peytavin; Michel Biour; Annie Métro; Cecile Goujard; Anne-Marie Taburet; Cecile Lascoux; Xaviere Panhard; Jean-Marc Tréluyer; Dominique Salmon-Céron
Journal:  Fundam Clin Pharmacol       Date:  2009-08       Impact factor: 2.748

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.